AI-based early-warning screening program for prostate and bladder cancer in men in Beijing

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project will implement an AI-based early-warning and screening pathway that begins with screening in community hospitals, moves definitive diagnosis to secondary hospitals, and directs treatment to tertiary centers. The system will support multi-institutional and multi-terminal sharing of disease information to enable dynamic monitoring, referral tracking, and follow-up. Male permanent residents of Beijing aged 50 and older will be enrolled to complete screening tests and questionnaires and to participate in longitudinal follow-up; no experimental therapy is given. Feasibility and effectiveness of the pathway will be tested using statistical analysis of screening, referral, diagnostic, and outcome data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male community residents aged 50 years or older;

Life expectancy \> 10 years and ECOG performance status of 0-2;

Permanent residents of Beijing who are willing to cooperate with researchers in the screening process, complete required tests and questionnaires, and participate in subsequent follow-up;

Support for the research project and provision of signed informed consent.

Exclusion Criteria:

* 1）Presence of any other malignant tumor or pre-existing prostate malignancy; 2）Presence of prostatitis or active infection in other parts of the urinary system; 3）Inability to cooperate with the study procedures or other factors deemed unsuitable for participation in this study.

Where it's running

• Department of Urology, Peking University First Hospital, Beijing, 100034
  Beijing, China Recruiting

Study contacts

• Study coordinator: Zejin Ou
• Email: 1522065106@qq.com
• Phone: 17310018392

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.